Advertisement

Topics

Novartis Canakinumab (ACZ885) Reduced Cardiovascular Risk by 25% in Subgroup of CANTOS Phase III ...

19:00 EST 12 Nov 2017 | BioSpace

The study was presented by Dr. Paul Ridker at the AHA Scientific Sessions 2017 and published simultaneously in The Lancet.

Original Article: Novartis Canakinumab (ACZ885) Reduced Cardiovascular Risk by 25% in Subgroup of CANTOS Phase III ...

NEXT ARTICLE

More From BioPortfolio on "Novartis Canakinumab (ACZ885) Reduced Cardiovascular Risk by 25% in Subgroup of CANTOS Phase III ..."

Advertisement
Quick Search
Advertisement
Advertisement